Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.88% is 49% above its 5-year average of -47.09%, near the high end of its 5-year range (-82.68%–-23.88%).
66.67% above its 12-month average of -71.64%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.38%.
RETURN ON ASSETS (ROA)
-23.88%
RETURN ON ASSETS (ROA) AVG TTM
-71.64%
RETURN ON ASSETS (ROA) AVG 3Y
-51.89%
RETURN ON ASSETS (ROA) AVG 5Y
-47.09%
RETURN ON ASSETS (ROA) AVG 10Y
-48.36%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+66.67%
CURRENT VS 3Y AVG
+53.98%
CURRENT VS 5Y AVG
+49.29%
CURRENT VS 10Y AVG
+50.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.11%
median of 604 covered companies
CURRENT VS SECTOR MEDIAN
+17.97%
vs the sector median at left
InflaRx N.V.
Market Cap
$238.61M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$236.58M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$243.64M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$243.81M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$237.74M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$237.27M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$241.61M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$235.77M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$232.19M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InflaRx N.V. (IFRX) | $238.61M | -23.88% | -71.64% | -51.89% | -47.09% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | -114.79% | -67.19% | -63.94% | -45.91% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.64M | -244.25% | -369.36% | -230.97% | -157.86% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | -14.72% | -16.00% | -18.82% |
| Galectin Therapeutics Inc. (GALT)vs › | $237.74M | -187.80% | -213.40% | -188.65% | -151.14% |
| High Tide Inc. (HITI)vs › | $237.27M | -8.99% | -7.90% | -14.69% | -13.78% |
| Invivyd, Inc. (IVVD)vs › | $241.61M | -49.04% | -75.08% | -74.95% | -71.96% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.77M | -8.48% | -16.43% | -20.20% | -32.31% |
| BioAge Labs Inc. (BIOA)vs › | $232.19M | -23.80% | -23.59% | -108.30% | -108.30% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.48M | -34.24% | -52.06% | -53.17% | -44.53% |
ROA
-23.9%
ROE
-27.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -82.68% |
| 2024-12-31 | -60.60% |
| 2023-12-31 | -35.49% |
| 2022-12-31 | -28.79% |
| 2021-12-31 | -36.46% |
| 2020-12-31 | -38.52% |
| 2019-12-31 | -43.80% |
| 2018-12-31 | -18.73% |
| 2017-12-31 | -19.51% |
| 2016-12-31 | -30.28% |
| 2015-12-31 | -137.12% |
